Erythema nodosum leprosum (ENL), or type II reaction, is a common complication of lepromatous leprosy that can cause significant patient debility. First-line therapy includes prednisone and thalidomide, with clofazimine reserved for patients who do not respond to first-line treatment. We present the case of a 33-year-old woman with ENL that failed to respond adequately to conventional therapy over a 6-year period. Because of the severe nature of her disease and the adverse effects of therapy that she experienced, a trial of etanercept was undertaken, which led to full resolution of her ENL. The rationale behind our choice of therapy and its future implications are discussed.
BT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America C1 - http://www.ncbi.nlm.nih.gov/pubmed/21292656?dopt=Abstract DA - 2011 Mar 01 DO - 10.1093/cid/ciq213 IS - 5 J2 - Clin. Infect. Dis. LA - eng N2 -Erythema nodosum leprosum (ENL), or type II reaction, is a common complication of lepromatous leprosy that can cause significant patient debility. First-line therapy includes prednisone and thalidomide, with clofazimine reserved for patients who do not respond to first-line treatment. We present the case of a 33-year-old woman with ENL that failed to respond adequately to conventional therapy over a 6-year period. Because of the severe nature of her disease and the adverse effects of therapy that she experienced, a trial of etanercept was undertaken, which led to full resolution of her ENL. The rationale behind our choice of therapy and its future implications are discussed.
PY - 2011 SP - e133 EP - 5 T2 - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America TI - Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. UR - http://cid.oxfordjournals.org/content/52/5/e133.full.pdf+html VL - 52 SN - 1537-6591 ER -